David McMahon

Director @Riverway Consulting Ltd

Windsor, CA

We help UK and EU based Medical Device companies to maximise exit valuations by developing and commercialising products for the US marketplace representing 50% of Global Sales. In a marketplace with very different incentives to the European Healthcare model we address the fundamental challenges: How (much) will the device be reimbursed? What is the optimal route to approval? How do I address the needs of the US Healthcare system whilst also addressing the economic imperatives of all key stakeholders? How can I efficiently launch and build data for my product in the US market? Which physicians and sites should I target for endorsement (KOLs) and sales revenue?Select list of engagementsCamdiab, Cambridge UK Commercial Strategy Advisor for Hybrid Closed Loop Artificial Pancreas appCyted, Cambridge UKUS Go to Market Strategy for novel test for Barrett’s Oxford UKUS Go to Market Strategy for Wearable Cueing Device for Parkinson’sHealth Technology Accelerator Facility, Edinburgh UKUS Commercial Market Assessment for Confidence in Concept projectsLivanova, London UKInternational Distributor Distribution management post acquisition of Sleep Apnea Implantable and Cardiac Life Support assetsProthea Technologies, Edinburgh UKMarket Assessment for novel Lung Cancer Diagnosis and Treatment Devicehttps://prothea.tech/newsitems/prothea-technologies-launches-with-e12m-series-a-to-innovate-lung-cancer-diagnosis-and-treatment-6/USATherm, Miami USAHead of Product for 510k approved Thermography productVB Devices, Barcelona SpainUS Go to Market Advisor for Drug Device Sclerotherapy therapy for Varicose VeinsVeryan, London UKUS Market opportunity assessment for novel Vascular DeviceVicentra, Utrecht NetherlandsUK Launch Strategy for Kaleido Insulin Pumphttps://hellokaleido.com/vicentra-raises-85m-to-scale-manufacturing/

London Business School

MBA, Business

University of Cambridge

BA, History